APLMW
Apollomics, Inc.
Set alert
- YTD
- +6.25%
- 1 year
- +6.25%
- Open
- 0.0167
- Prev close
- 0.0104
- Mkt cap
- 33.17M
- Vol
- 11.26K
- Avg vol
- 0
- EPS
- -4.34
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.0112
- High
- 0.0124
- Forward P/E
- 0.00
- Beta
- 0.00
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 0.026
- 200-d avg
- 0.026
- 1y target
- 0.00
News
2 months ago globenewswire.com
Apollomics Announces $10 Million Private Placement Transaction
FOSTER CITY, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM ) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology…
3 months ago globenewswire.com
Apollomics Regains Full Compliance with Nasdaq Listing Requirements
FOSTER CITY, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM ) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology…
4 months ago globenewswire.com
Apollomics Receives Nasdaq Deficiency Notice Regarding Minimum Market Value Requirement and Updates Rights for Vebreltinib (APL-101) in Asia
FOSTER CITY, Calif., June 24, 2026 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM ) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology…
6 months ago globenewswire.com
Apollomics Reports Full Year 2025 Financial Results and Provides Clinical Updates and Business Progress
Phase 2 studies ongoing to advance global development of vebreltinib, a highly potent, de-risked and differentiated c-MET Inhibitor with best-in-class and first-in-class potential. To date, more than…
7 months ago globenewswire.com
Apollomics Inc. Announces $2.0 Million Bridge Financing
FOSTER CITY, Calif., April 01, 2026 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), today announced that it has entered into a $2.0 million unsecured Convertible…
10 months ago globenewswire.com
Apollomics Reports First Half 2025 Financial Results
FOSTER CITY, Calif., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM ) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology…
11 months ago globenewswire.com
Apollomics Announces Settlement of Cayman Litigation
FOSTER CITY, Calif., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”) (Nasdaq: APLM) announced today entering into a settlement agreement (the “Settlement Agreement”…
11 months ago globenewswire.com
Apollomics Announces Changes to its Board of Directors and Composition of Committees
FOSTER CITY, Calif., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a California-based late-stage clinical biopharmaceutical company, today…
1 year ago globenewswire.com
Apollomics Announces Continued Listing on The Nasdaq Stock Market Following Hearing Cancellation
FOSTER CITY, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a California based late-stage clinical biopharmaceutical company developing…
-
1 year ago benzinga.com
Nasdaq To Resume Trading In Apollomics Shares And Warrants On October 15, 2025
The Nasdaq Stock Market® (NASDAQ:NDAQ) announced that trading will resume in Apollomics Inc. Class A ordinary shares (NASDAQ:APLM) and warrants (NASDAQ:APLMW) at 9:00 a.m. and 9:05 a.m. Eastern Time,…
1 year ago globenewswire.com
Nasdaq Resumes Trading in Apollomics Inc.
NEW YORK, Oct. 14, 2025 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market® (Nasdaq: NDAQ) announced that trading will resume in Apollomics Inc. Class A ordinary shares (Nasdaq: APLM) and warrants (Nasdaq:…
1 year ago globenewswire.com
Apollomics, Inc. Company Operational Continuity Update
FOSTER CITY, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), today announced the following company operational update.
1 year ago globenewswire.com
Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress
FOSTER CITY, Calif., April 03, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to…
1 year ago globenewswire.com
Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib
FOSTER CITY, Calif. and TAIPEI, Taiwan, March 31, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics”), a late-stage clinical biopharmaceutical company developing multiple oncology…
1 year ago globenewswire.com
Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia
FOSTER CITY, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology…
1 year ago globenewswire.com
Apollomics Regains Compliance with Nasdaq's Minimum Bid Price Requirement
FOSTER CITY, Calif., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (the “Company”), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat…
2 years ago globenewswire.com
Apollomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
FOSTER CITY, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology…
2 years ago globenewswire.com
Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical Progress
FOSTER CITY, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology…
2 years ago globenewswire.com
Apollomics Announces Positive Preliminary Data of Vebreltinib in Patients with Non-CNS MET Fusion Solid Tumors from its Phase 2 SPARTA Trial
43% overall response rate: Six confirmed responses (including one complete response in metastatic non-small cell lung cancer and five partial responses) confirmed by RECIST 1.1 out of 14 patients…
2 years ago globenewswire.com
Apollomics Granted 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Requirement
FOSTER CITY, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology…
2 years ago globenewswire.com
Apollomics Announces Updated Strategic Focus and Leadership Team Changes
Focus on vebreltinib study enrollment for non-small cell lung cancer (NSCLC) patients with Met Amplification mutations targets greatest unmet medical need Focus on vebreltinib study enrollment for…
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Thursday
During Thursday's session, 406 companies made new 52-week lows.